Success of the first cell transplant with tissue engineering in type 1 diabetes

The graft has been performed in the Epiplón, a region of irrigation and drainage similar to those of the pancreas and that allows minimally invasive surgery.

The New England Journal of Medicine has published the results of the first clinical trial that demonstrates the viability of the pancreatic islet transplantation generated on a tissue engineering platform.The study is part of a clinical program aimed at determining if this strategy can offer definitive replacement therapy for millions of patients suffering from type 1 diabetes.

The islet transplant has been traditionally made in the liver, a location that imposes certain limitations.The current essay has used the epiplón as a receiver, a membranous layer of fatty tissue that surrounds and supports the viscera of the lower region of the abdomen.

This is achieved that the implant is irrigated and drained similarly to the pancreas, while facilitating laparoscopy.Camillo Ricordi, director of the trial, states that this is the first mini-pancreas generated by tissue engineering that achieves long-term exogenous insulin independence.The implant has been created by combining the islets of a donor with blood plasma of the patient.

The implementation process includes the addition of thrombin, which creates a gelatinous layer that facilitates the adhesion of the implant to the epiplón and is later reabsorbed by the body.

This procedure minimizes the inflammatory reaction typically observed in liver implants or in direct contact with the blood.

I just wanted it and the patient does take immuno-suppressors.

Link

I've been reading these experiments for 25 years and always do the same:

After much investigating with animals, they first prove it in a diabetic but without the capsule and with immunosuppressive drugs with what they ensure media success (hiding the fact of no capsule and if anti-recreational drugs) and in the actions of thecompany.

Then they try it with the capsule in the same patient, who already has the previous transplant and the immunosuppressants that work, but hiding this finally to the media, which ensures another media success.

Then they finally prove it in diabetics without immuno-suppression but they say that with few cells to test the minimum dose or safety (but you have already tried it many times!) So although it never works they say they are normal, but like theCompany really sees that the improvement is zero no longer.

Why don't all the intermediate steps skip that are absolutely useful for anything except to waste their time and publish useless things?Why don't they directly test the capsule with cells in patients without immunosuppression?

Already, and there are more problems ... where are they going to get so many cells for the transplant? ..., hopefully I am wrong, but this is still very green ..